[Federal Register Volume 60, Number 3 (Thursday, January 5, 1995)]
[Notices]
[Pages 1792-1793]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-202]



=======================================================================
-----------------------------------------------------------------------
[[Page 1793]]

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-358]


Certain Recombinantly Produced Human Growth Hormones; Notice of 
Commission Determination Not To Review an Initial Determination 
Granting Complainant's Motion To Amend the Complaint and Notice of 
Investigation To Withdraw a Patent Claim

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined not to review the presiding administrative 
law judge's (ALJ's) initial determination (ID) in the above-captioned 
investigation granting complainant Genentech, Inc.'s motion to amend 
the complaint and notice of investigation by withdrawing claim 38 of 
U.S. Letters Patent 5,221,619 from the investigation.

FOR FURTHER INFORMATION CONTACT: Mark D. Kelly, Esq., Office of the 
General Counsel, U.S. International Trade Commission, telephone 202-
205-3106.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on September 29, 1993, based on a complaint filed by Genentech, Inc. of 
South San Francisco, California. 58 FR 50954. The following five firms 
were named as respondents: Novo Nordisk A/S of Denmark; Novo Nordisk of 
North America, Inc. of New York; ZymoGenetics, Inc. of Seattle, 
Washington (collectively, ``the Novo respondents''); Bio-Technology 
General Corp. of New York; and Bio-Technology General Corp. (Israel) 
Ltd. (collectively, ``the BTG respondents'').
    At the pre-hearing conference on April 8, 1994, complainant 
Genentech orally moved to amend the complaint by withdrawing claim 38 
of the '619 patent from the investigation. The parties addressed 
complainant Genentech's motion in their post-hearing submissions. The 
Commission investigative attorneys (IAs) supported complainant's 
motion. The Novo respondents and the BTG respondents opposed 
complainant's motion. No petitions to review the ID were filed and no 
government agency comments were received.
    This action is taken under the authority of section 337 of the 
Tariff Act of 1930, 19 U.S.C. 1337, and Commission interim rule 210.53 
(19 C.F.R. 210.53).
    Copies of the ID and all other nonconfidential documents filed in 
connection with this investigation are or will be available for 
inspection during official business hours (8:45 a.m. to 5:15 p.m.) in 
the Office of the Secretary, U.S. International Trade Commission, 500 E 
Street S.W., Washington, DC 20436, telephone 202-205-2000. Hearing-
impaired persons are advised that information on the matter can be 
obtained by contacting the Commission's TDD terminal on 202-205-1810.

    Issued: December 28, 1994.

    By order of the Commission.
Donna R. Koehnke,
Secretary.
[FR Doc. 95-202 Filed 1-4-95; 8:45 am]
BILLING CODE 7020-02-P